{"symbol":"REGN","fiscalQuarter":"Q4-2023","reportDate":"2024-02-02","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2023","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.32%","keyNumbers":[{"metric":"EPS","actual":"$11.86","expected":"N/A","surprise":"+30.32%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on innovation and delivering value to patients."],"summary":"Management expressed satisfaction with the earnings beat on EPS. They emphasized their commitment to innovation and patient care."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue data. The stock's slight decline of 1.32% may reflect investor caution or profit-taking after the earnings announcement. Overall, the results suggest a solid financial position, but the absence of revenue details leaves some uncertainty.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2023 earnings: EPS beat by 30.32%. Stock down 1.32%. Full breakdown."}}